C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi,Gunnar Birgegård,Guido Finazzi,Martin Griesshammer,Claire N. Harrison,Hans Carl Hasselbalch,Jean Jacques Kiladijan,Eva Lengfelder,Ruben A. Mesa,Mary F. Mc Mullin,Francesco Passamonti,John T. Reilly,Alessandro M. Vannucchi,Tiziano Barbui +13 more
TL;DR: A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis : results of a European LeukemiaNet (ELN) consensus process are published.
Journal ArticleDOI
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia
TL;DR: This study investigated 60 patients with ET for the presence of the JAK2 mutation and possible phenotypic associations and used the previously published allele-specific polymerase chain reaction (PCR) method on whole blood DNA to detect qualitatively the presence or absence of theJAK2 V617F mutation.
Journal ArticleDOI
Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
Peter J. Campbell,David Bareford,Wendy N. Erber,Bridget S. Wilkins,Penny Wright,Georgina Buck,Keith Wheatley,Claire N. Harrison,Anthony R. Green +8 more
TL;DR: Patients receiving anagrelide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who show substantially increasing reticulin levels are at risk of myelofibrotic transformation and may benefit from changing therapy before adverse clinical features develop are suggested.
Journal ArticleDOI
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
TL;DR: Pregnancy outcomes in inherited thrombophilia and antiphospholipid antibody syndrome pregnancy outcomes in these conditions parallel those reported for MPDs, and a personal management strategy for pregnancy in MPD proposed.
Journal ArticleDOI
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Alvarez-Larrán,Arturo Pereira,Paola Guglielmelli,Juan Carlos Hernández-Boluda,Eduardo Arellano-Rodrigo,Francisca Ferrer-Marín,Alimam Samah,Martin Griesshammer,Ana Kerguelen,Bjorn Andreasson,Carmen Burgaleta,Jiri Schwarz,Valentín García-Gutiérrez,Rosa Ayala,Pere Barba,María Teresa Gómez-Casares,Chiara Paoli,Beatrice Drexler,Sonja Zweegman,Mary Frances McMullin,Jan Samuelsson,Claire N. Harrison,Francisco Cervantes,Alessandro M. Vannucchi,Carlos Besses +24 more
TL;DR: In patients with low-risk, CALR-mutated essential thrombocythemia, low-dose aspirin does not reduce the risk ofThrombosis and may increase therisk of bleeding.